Enhancing oncogenic signaling to kill cancer cells

Maxim Noeparast; Oleg Timofeev; Martin Pichler

doi:10.1016/j.tips.2024.04.011

Enhancing oncogenic signaling to kill cancer cells

Trends Pharmacol Sci. 2024 May 10:S0165-6147(24)00091-9. doi: 10.1016/j.tips.2024.04.011. Online ahead of print.

Authors

Maxim Noeparast¹, Oleg Timofeev², Martin Pichler³

Affiliations

¹ Translational Oncology, II. Med Clinics Hematology and Oncology, 86156, Augsburg, Germany. Electronic address: maxim.noeparast@uk-augsburg.de.
² Institute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University, 35043 Marburg, Germany.
³ Translational Oncology, II. Med Clinics Hematology and Oncology, 86156, Augsburg, Germany.

PMID: 38734500
DOI: 10.1016/j.tips.2024.04.011

Abstract

Cancer-targeted therapies that inhibit oncogenic signaling often lead to resistance and recurrence. In a recent study, Dias et al. propose activating oncogenic pathways and inducing replication stress, resulting in cell death and tumor-suppressive mechanisms in colorectal cancer (CRC). This approach could spark a new wave of target discovery, and drug development and repurposing against cancer.

Keywords: LB-100; adavosertib; oncogenic agonism; paradoxical pathway activation.